Dr. Guy Godwin is a Chief Medical Officer for Compass pathways, working to re-medicalize psychedleic drugs for us in psychiatry.
He is Emeritus Professor of Psychiatry and NIHR Emeritus Senior Investigator at the University of Oxford, UK. His research interests are the treatment of mood disorder and the potential to improve treatment using new technology and new drugs, notably the psychedelics.
He is a Fellow of the American College of Neuropsychopharmacology, has previously held the position of President of the British Association for Psychopharmacology and the European College of Neuropsychopharmacology (ECNP) and is a Senior Investigator on the faculty of UK National Institute for Health Research (NIHR).